sector medic suppli devic
initi coverag buy
messag initi coverag buy rate pt csi
product becom tool choic mani physician aid treatment
heavili calcifi lesion back high level clinic evid
recent manag embark plan diversifi portfolio target new
product launch next year combin ramp ou expans effort
see csi well posit acceler top line growth believ street
underestim potenti inflect expect improv sentiment multipl
expans drive out-performance stock visibl dynam improv
csi made name tack tough case heavili calcifi plaqu
peripher coronari arteri among difficult physician treat
tradit intervent devic balloon stent often fail adequ
reopen clog vessel expos patient increas risk futur complic
csi diamondback orbit atherectomi system address mani limit
innov design allow sand away hard calcif nodul leav
healthi tissu unharm result becom tool choic mani
physician encount calcifi lesion gener sale csi
commit innov develop high qualiti clinic evid
csi posit penetr estim
procedur perform annual revascular calcifi peripher
coronari arteri yet diamondback use less last year
drive adopt technolog csi lead clinic evid
peripher side data liberti all-com registri continu suggest
improv outcom compar altern treatment approach build
result random calcium complianc trial elsewher
csi current halfway toward complet enrol ambiti eclips studi
seek establish standard care calcifi coronari arteri meanwhil
innov front view enhanc facilit radial access easier
treatment multilevel diseas import new growth driver potenti
lead increas penetr
elsewher see manag plan diversifi product portfolio captur
revenu per procedur underappreci growth opportun
seri recent upcom launch csi build line-up accessori product
support almost everi aspect case process estim compani
open increment potenti revenu per procedur
peripher coronari side respect base case scenario reflect
estim assum util product ramp csi caseload
next four year contribut revenu forecast consensu
period bull case scenario adopt estim grow
contribut accessori revenu could add increment sale
consid potenti impact earlier stage pipelin program direct
atherectomi pvad current assign valu
model call csi grow sale compound-annual-growth-rate importantli
see compani growth acceler period
driven ramp adopt intern expans
higher revenu per procedur visibl acceler increas expect
improv investor sentiment upsid street number drive multipl expans
out-performance stock
initi buy price target base multipl
forward ntm sale estim impli upsid current level
page analyst certif import disclosur
cardiovascular system inc st paul minnesota base medic devic compani
focus develop commerci solut treatment peripher
coronari arteri diseas compani proprietari orbit atherectomi system
first design receiv fda approv treatment lesion
leg heart highli competit field csi distinguish
year focus challeng patient particularli
heavili calcifi arteri difficult address tradit intervent tool
result technolog becom first choic mani clinician
encount sever calcium unit sold global last year
left right diamondback peripher system classic solid micro crown diamondback coronari system
recent csi manag team embark plan diversifi compani
revenu base leverag larg experienc sale forc broaden product
portfolio includ mani tool use case believ strategi
potenti drive acceler compani top line growth next
year time improv profit increas rep product
long-term csi announc plan branch adjac
direct atherectomi hemodynam support could expand total
address market combin intern roll-out still earli stage
today see multipl avenu potenti growth csi go forward
model call csi revenu climb recent complet
impli compound-annual-growth-rate forecast assum core
busi grow clip driven strong underli trend complex pci
peripher vascular procedur volum expect intern sale ramp
last year compound-annual-growth-rate csi make inroad japan feb
launch benefit intern distribut agreement sign
orbusneich juli final expect csi non-oa revenu rise
compound-annual-growth-rate driven increas adopt
compani accessori product line model call csi overal top-lin growth rate
acceler inflect
believ potenti drive multipl expans stock visibl
individu compon acceler improv
page analyst certif import disclosur
made name tackl tough case
compani orbit atherectomi system design address mani limit
tradit intervent technolog heavili calcifi vessel stent balloon reli
radial forc push plaqu way open diseas arteri easi task
soft fibrot lesion hard calcium nodul prevent full expans devic
howev lead sub-optimal result increas risk futur complic due
residu stenosi vessel new issu brought stent malapposit csi
peripher coronari devic single-us cathet incorpor control
handl flexibl drive shaft eccentr mount diamond-co crown
crown steer site lesion time drive shaft engag rapidli
spin crown vessel wall friction crown sand away calcium
nodul compliant vessel wall flex spin drive shaft
unharm calcium reduc fine particul smaller size red
blood cell ensur safe outcom patient lesion clear
stent balloon deploy complet revascular procedur
clockwis top left calcium nodul form insid atherosclerot arteri plaqu build-up imped blood flow downstream tissu orbit
atherectomi sand away calcif plaqu without damag healthi tissu stent balloon optim deploy within diseas arteri
complet revascular procedur
csi flagship product diamondback system origin receiv fda
approv via pathway peripher arteri system primarili
use vessel prepar enabl low pressur balloon angioplasti either plain
drug-coat balloon system featur portfolio three uniqu crown design solid
classic micro address variou vessel size locat combin
crown give physician abil target even narrow tortuou vessel
page analyst certif import disclosur
csi particular success drive adopt knee btk
small tortuou vessel limit effect technolog estim
compani peripher case involv btk lesion today mix
steadili increas time
beyond develop innov technolog csi also separ
pack commit gener high qualiti clinic evid someth
histor lack peripher vascular space diamondback
origin approv base evid oasi pivot trial
patient treat experienc target lesion revascular rate
mace rate month despit studi enrol complex popul csi
follow liberti all-com registri
claudic critic limb ischemia patient could treat fda-approv
technolog result subgroup strong across board
random trial outcom difficult patient rutherford class
numer better diamondback treatment approach
csi also gener random data calcium btk
complianc atk studi compar orbit atherectomi plu
balloon angioplasti balloon angioplasti alon calcium btk patient treat
diamondback like free major advers event month
vs includ need target lesion revascular vs
meanwhil procedur less like requir bailout stent vs
result achiev despit arm enrol tougher popul
includ significantli diabet patient complianc demonstr similar
outcom atk lesion patient experienc numer higher primari
patenc rate month vs despit lower balloon inflat pressur
vs dramat reduc stent util vs
look ahead csi recent complet enrol studi
compar vessel prepar orbit atherectomi prior drug-coat balloon
deploy dcb alon treatment calcifi btk lesion concern
possibl late mortal signal paclitaxel elut peripher balloon stent put
damper drug-coat balloon market recent thrown wrench becton
dickinson plan secur btk indic lutonix dcb
page analyst certif import disclosur
expect dcb util rebound gradual clinic evid call
question verac mortal signal meantim believ posit data
due would posit csi well promot combin therapi
oa dcb prefer treatment option dcb use knee eventu
take
elsewher compani recent enrol first patient reach pvi studi
design evalu use deliv via radial access treatment
pad radial approach gain popular coronari intervent
pci perform use techniqu oppos transfemor access shift
driven desir reduc complic associ access site closur
take advantag opportun earlier patient ambul wrist use
achiev vascular access rather groin csi believ physician
increasingli embrac radial access peripher procedur well uniqu
posit benefit shift given small deliveri profil vs
competit atherectomi system abil treat whole lesion without
remov devic midway dispos excis plaqu capit radial trend
csi develop full suit product facilit approach ramp physician
train includ recent introduc version diamondback
manag expect full toolkit market end result
reach pvi support initi trial track read late
believ expand radial portfolio drive share gain csi
hospit office-bas lab set compani alreadi experienc
strong momentum manag note call account adopt
radial grew sequenti last quarter abil perform case radial
particularli appeal obl minim complic get patient
feet quickli post procedur import profit center obl
account peripher atherectomi procedur today volum grow
faster market overal due favor reimburs csi tradit
smaller presenc lab due diamondback premium asp compani
focu complex procedur often perform hospit set
began chang late howev csi start offer high-volum obl long-
term volume-bas contract increas procedur support enabl complex
caseload put increment pressur compani
strategi paid thu far csi peripher sale come
set revenu grow clip past three quarter compani
call less half obl today believ on-going
penetr set could act tailwind year come
page analyst certif import disclosur
approvalu pivot trial diamondback data pta vs pta data pta vs pta data pta evalu use ivu imagingaug dataal comer registri releas dcb vs dcb pviatk releas pad via radial access medic suppli devic
csi receiv pma approv market diamondback treatment
sever calcifi coronari arteri lesion procedur basic
heart leg system use primarili prep heavili calcifi coronari
vessel drug-elut stent implant often among challeng
cad patient physician treat due difficulti achiev optim stent
deploy calcifi lesion risk associ leav stent strut
malappos orbit ii pivot trial diamondback deliv
procedur success rate patient treat free mace day
post procedur studi later follow coast trial
enrol patient site japan achiev similar acut long-
term outcom arm clinic evid csi made steadi progress grow
coronari busi past year coronari procedur contribut
overal revenu vs
figur orbit ii coast acut result
figur orbit ii coast outcom
go forward believ eclips potenti establish standard
care heavili calcifi coronari arteri despit csi recent progress
atherectomi still wide underutil coronari accord clinic literatur
sever calcifi lesion make pci equat annual
procedur global howev coronari atherectomi util less pci
procedur drive adopt csi initi eclips trial
random patient sever calcifi coronari arteri either vessel
prepar convent balloon angioplasti prior de implant
eclips repres largest random atherectomi trial ever conduct csi
hope evid studi support guidelin chang recommend
calcifi lesion manag current target enrol complet
page analyst certif import disclosur
approvalu pivot trial diamondback dataoa micro crown prior enrollmentoa de vs pta de medic suppli devic
peripher arteri diseas pad potenti life-threaten condit character
narrow harden arteri leg result significantli reduc blood flow
leg feet left untreat pad progress critic limb ischemia
stage volum oxygen blood deliv limb insuffici
keep tissu viabl sometim result need amput peripher
market segment above-the-kne atk below-the-kne btk lesion atk
diseas typic easier treat arteri upper leg larger less tortuou
easier access btk vessel
american heart associ aha estim american form
peripher arteri diseas patient age preval
estim rise popul age diseas contribut pad
diabet obes becom common despit frequenc pad remain
underdiagnos due lack physician patient awar patient
identifi treatment usual begin prescript drug statin
recommend lifestyl chang relat diet exercis conserv
therapi may temporarili improv blood flow dont address underli vascular
occlus result mani patient develop sever symptom time
american pad csi estim diagnos
intermitt claudic less sever still clinic signific form diseas
equat potenti market opportun realist
fraction patient like receiv treatment due patient referr
challeng cite believ conserv start point roughli
patient undergo peripher intervent year includ amput
revascular procedur roughli revascular
includ form atherectomi today diamondback use case
overal segment grow high single-digit clip howev csi estim
peripher revascular perform annual involv
calcifi lesion impli potenti compani
penetr date
page analyst certif import disclosur
shortag devic approv treatment pad broadli
believ csi remain best option heavili calcifi lesion
player atherectomi market hawk famili direct atherectomi system
silverhawk turbohawk hawkon devic use catheter-mount cut
blade shave plaqu vessel wall collect nosecon remov
bodi histor strongest knee segment
market due larger cathet size mani physician gravit devic
case involv soft fibrou plaqu shorter lesion avoid frequent
remov system empti nosecon
boston scientif jetstream atherectomi devic continu aspir plaqu
excis therebi elimin need frequent remov reinsert cathet
devic use remov atherosclerot debri also thrombu make
ideal lesion mix morpholog plaqu thrombu elsewher philip
acquir spectranet turbo power laser atherectomi system
spectranet busi skew toward complex case includ btk lesion
in-stent restenosi procedur laser perform best long diffus plaqu
low level calcium
beyond atherectomi gain fda approv use intravascular
lithotripsi ivl technolog treatment pad juli ivl leverag
principl use urolog lithotripsi treatment that around year
break kidney stone ivl procedur balloon cathet first posit across
calcifi lesion rapid electr discharg vapor fluid within balloon creat
pulsatil sonic pressur wave wave pass harmlessli soft tissu exert
enough pressur high-dens calcium crack calcium disrupt
arteri expand low pressur believ signific physician
interest ivl new treatment option use peripher arteri
somewhat constrain date poor reimburs sens much
shockwav current procedur volum come vascular bed
atherectomi devic either ineffect contraind common femor
iliac arteri combin procedur physician alreadi use
highli reimburs technolog tavr impella
final dont believ recent controversi surround paclitaxel coat
peripher devic major impact csi busi drug-coat balloon
upend pad competit landscap burst onto scene
back robust clinic evid demonstr superior tradit
pta philip becton dickinson drug-coat peripher balloon
approv boston scientif ranger dcb track fda approv
util devic fell sharpli earlier year meta-analysi
variou trial identifi late risk increas mortal patient treat dcb
compar other receiv pta data emerg challeng conclus
sens pendulum swing back way dcb util
pois rebound meantim dont believ reduc dcb volum
meaning impact csi busi dcb primarili use hospit set
atk lesion segment repres csi peripher busi
compani overal revenu heavili calcifi lesion physician
often turn vessel prep necess regardless whether finish
treatment dcb pta stent result see csi limit exposur
dynam
page analyst certif import disclosur
accord aha peopl suffer coronari arteri diseas cad
common form heart diseas cad life-threaten condit occur
fatti materi call plaqu build wall arteri suppli blood
heart caus arteri harden narrow atherosclerosi imped blood
flow patient cad often experi sever chest pain call angina left
untreat cad lead myocardi infarct heart attack death
almost american undergo pci procedur year treat cad see figur
past decad mix patient refer stent open clog
coronari arteri shift includ complex diseas trend driven
mount clinic evid pci improv clinic outcom stabl
cad patient introduct new technolog abiom impella
pump keep high-risk patient hemodynam stabl undergo
procedur thu make treatment option patient might previous
turn csi estim high-risk pci perform year
 involv moderate-to-sever calcium impli
market opportun estim coronari atherectomi market
closer today csi hold market share expect segment
grow mid-teen rate go forward driven strong underli procedur trend
csi diamondback system devic specif indic
treatment sever calcifi coronari arteri boston scientif rotabl
use lesion sinc first approv rotabl rotat
atherectomi system use front-cut diamond-tip burr sand away calcif
nodul one key drawback rotabl compar diamondback size
lumen creat rotabl burr center stabl guidewir
channel clear wide diamet burr compar
eccentr posit diamondback crown creat centrifug forc push
burr outward vessel wall spin allow diamondback creat
channel much wider crown size vessel determin
page analyst certif import disclosur
recent tct confer data present propensity-match analysi
patient treat either diamondback rotabl within bcb
michigan cardiovascular consortium technolog perform well
achiev high rate acut procedur success complic event rate
numer favor includ signific reduct dissect
overal see csi well posit continu take share boston cad
longer term expect shockwav carv presenc cad well result
compani disrupt cad ii trial also present tct demonstr
clinic success rate low residu stenosi complic
one blemish incid non-q wave mi shockwav product
receiv ce mark may enrol disrupt cad pivot trial
on-going put track potenti fda approv
novemb csi sign exclus distribut agreement medikit sell
coronari peripher product japan csi receiv japanes regulatori
approv coronari system month later commerci launch kick
februari csi estim pci perform annual
involv heavili calcifi lesion impli opportun
sale repres solid start csi primarili focus coronari
opportun japan today manag expect begin enrol clinic studi
support peripher indic next month could put compani track
launch peripher portfolio japan late earli
juli csi announc distributor agreement orbusneich sell coronari
peripher product market outsid japan orbusneich
manufactur sell extens portfolio coronari peripher devic includ
stent angioplasti balloon microcathet make complementari addit
exist line-up direct sale rep presenc countri
orbusneich agreement allow csi jumpstart intern expans without
invest creation global distribut network compani juli
analyst meet cfo jeffrey point laid target ou revenu ramp
forecast view achiev
page analyst certif import disclosur
juli analyst meet csi set ambiti goal gener
revenu intern innov underpin target plan bring
new product market next four year bolster core franchis
diversifi revenu base move new adjac would consid mani
product iter natur worth call believ success
critic csi achiev revenu goal
first radial toolkit touch earlier actual encompass
sever differ product includ extend length system launch
guidewir manag expect last three product list avail
earli second import addit core franchis exchang
peripher platform enabl physician easili treat pad
patient multi-level diseas util multipl crown size singl case
expect platform recent move full commerci launch particularli
attract econom driven physician oper office-
clockwis left exchang peripher platform wirion embol protect filter percutan
tct csi also announc plan develop direct atherectomi solut
project replac laser atherectomi program compani origin talk
analyst meet laser intrigu direct market much
larger vs complementari csi exist
franchis direct atherectomi primarili use treat soft atk lesion
compani hope differenti technolog on-board aspir greater cut
depth control cost manufactur could allow serv price sensit
custom obl intern market manag target first-in-man
procedur devic get clariti time potenti
commerci launch howev arent assum revenu contribut
product estim
page analyst certif import disclosur
one product recent ad csi pipelin wirion
embol protect filter compani acquir gardia medic
up-front anoth upon success complet manufactur transfer
expect first half above-the-kne atherectomi
procedur perform annual epd use case
estim use roughli atk case csi launch wirion
asp impli potenti market opportun
consid potenti filter use non-oa case intern
model assum wirion sale ramp
compani report guggenheim secur llc estim
final csi also disclos intent enter hemodynam support
market pump high-risk pci manag describ pvad system
low profil cross cathet high flow lpm pump easier
deliv abiom impella featur simpl user interfac csi state
hope begin fim procedur see hemodynam support logic white
space csi target given size market signific overlap
case involv impella see high-risk ventur howev
engin challeng associ safe move blood around bodi
signific result dont current assign valu program model
compani report guggenheim secur estim
page analyst certif import disclosur
